Patent · US Revoked

Alphavirus neoantigen vectors

US11419929B2 · kind B2 · utility

0Cited by
102References
30Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMay 8, 2018
Grant dateAug 23, 2022
Priority date
Expiry dateMay 8, 2038

Classification

  • Technology area (CPC —)General

Abstract

Disclosed herein are alphavirus vectors that include neoantigen-encoding nucleic acid sequences derived from a tumor of a subject. Also disclosed are nucleotides, cells, and methods associated with the vectors including their use as vaccines.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.